Ray Jupp joined SV as a Venture Partner in 2020. He is the Chief Scientific Officer of Mestag, a company founded and seed funded by SV in 2020.
Prior to joining Mestag, Ray was Chief Scientific Officer of TrexBio, and Enara, two SV-founded companies.
Prior to his move into biotech, Ray was head of the Immunology / Inflammation Therapeutic Area at UCB having joined in 2012. In this role he drove multiple compounds into development and through Phase 1 and 2 clinical trials.
Ray developed his interest in immunology having joined Roche in 1993 and set up a lab to discover novel anti-viral medicines. Ray contributed to Invirase, the first medicine developed against the proteinase encoded by HIV. He began his work on inflammatory / auto-immune diseases whilst at Rhone-Poulenc Rorer before returning to the US to head up Inflammation Biology for Aventis. Following the creation of Sanofi, he was appointed Head of Internal Medicine, extending his disease scope to include anti-fibrotics and infectious diseases moving over 10 compounds into development, several in collaboration with Regeneron.
Academic Credentials
PhD in Biochemistry from Cardiff University, followed by a post-doctoral fellowship at the Scripps Research Institute, San Diego.
